Broad Purpose Vector for Site-Directed Insertional Mutagenesis in
Overview
Authors
Affiliations
Members of the genus are notoriously recalcitrant to genetic manipulation due to their extensive and variable repertoire of Restriction-Modification (R-M) systems. Non-replicating plasmids are currently employed to achieve insertional mutagenesis in . One of the limitations of using such insertion vectors is the presence within their sequence of various restriction sites, making them sensitive to the activity of endogenous restriction endonucleases encoded by the target strain. For this reason, vectors have been developed with the aim of methylating and protecting the vector using a methylase-positive strain, in some cases containing a cloned bifidobacterial methylase. Here, we present a mutagenesis approach based on a modified and synthetically produced version of the suicide vector pORI28 (named pFREM28), where all known restriction sites targeted by R-M systems were removed by base substitution (thus preserving the codon usage). After validating the integrity of the erythromycin marker, the vector was successfully employed to target an α-galactosidase gene responsible for raffinose metabolism, an alcohol dehydrogenase gene responsible for mannitol utilization and a gene encoding a priming glycosyltransferase responsible for exopolysaccharides (EPS) production in . The advantage of using this modified approach is the reduction of the amount of time, effort and resources required to generate site-directed mutants in and a similar approach may be employed to target other ( species.
Kozakai T, Nakajima A, Miyazawa K, Sasaki Y, Odamaki T, Katoh T iScience. 2024; 27(11):111080.
PMID: 39502284 PMC: 11536034. DOI: 10.1016/j.isci.2024.111080.
Qian X, Li Q, Zhu H, Chen Y, Lin G, Zhang H Cell Rep Med. 2024; 5(11):101798.
PMID: 39471819 PMC: 11604549. DOI: 10.1016/j.xcrm.2024.101798.
Harnessing the endogenous Type I-C CRISPR-Cas system for genome editing in .
Han X, Chang L, Chen H, Zhao J, Tian F, Ross R Appl Environ Microbiol. 2024; 90(3):e0207423.
PMID: 38319094 PMC: 10952402. DOI: 10.1128/aem.02074-23.
Rizzo S, Vergna L, Alessandri G, Lee C, Fontana F, Lugli G Microb Biotechnol. 2024; 17(2):e14406.
PMID: 38271233 PMC: 10884991. DOI: 10.1111/1751-7915.14406.
Establishing genetic manipulation for novel strains of human gut bacteria.
Sheridan P, Odat M, Scott K Microbiome Res Rep. 2023; 2(1):1.
PMID: 38059211 PMC: 10696588. DOI: 10.20517/mrr.2022.13.